View in EDS HTML Full Text PDF Full Text

An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.

Saved in:
Bibliographic Details
Title: An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Authors: Kapoor P; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Nathwani N; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, California, USA., Jelinek T; Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic., Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Perrot A; Department of Hematology, Institut Universitaire du Cancer de Toulouse, Toulouse, France., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Huang SY; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan., Spicka I; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic., Chhabra S; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, Arizona, USA., Lichtman E; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain., Kanagavel D; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France., Zhao L; Research and Development, Sanofi, Research and Development, Shanghai, China., Guillemin-Paveau H; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France., Macé S; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France., van de Velde H; Research and Development, Sanofi, Research and Development, Cambridge, Massachusetts, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, Massachusetts, USA.
Source: European journal of haematology [Eur J Haematol] 2024 Nov; Vol. 113 (5), pp. 593-605. Date of Electronic Publication: 2024 Jul 12.
Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase I
Journal Info: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38993150
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kapoor+P%22">Kapoor P</searchLink>; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.<br /><searchLink fieldCode="AU" term="%22Nathwani+N%22">Nathwani N</searchLink>; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, California, USA.<br /><searchLink fieldCode="AU" term="%22Jelinek+T%22">Jelinek T</searchLink>; Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Pour+L%22">Pour L</searchLink>; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Perrot+A%22">Perrot A</searchLink>; Department of Hematology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Huang+SY%22">Huang SY</searchLink>; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Spicka+I%22">Spicka I</searchLink>; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Chhabra+S%22">Chhabra S</searchLink>; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, Arizona, USA.<br /><searchLink fieldCode="AU" term="%22Lichtman+E%22">Lichtman E</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Mateos+MV%22">Mateos MV</searchLink>; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.<br /><searchLink fieldCode="AU" term="%22Kanagavel+D%22">Kanagavel D</searchLink>; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Zhao+L%22">Zhao L</searchLink>; Research and Development, Sanofi, Research and Development, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Guillemin-Paveau+H%22">Guillemin-Paveau H</searchLink>; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Macé+S%22">Macé S</searchLink>; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22van+de+Velde+H%22">van de Velde H</searchLink>; Research and Development, Sanofi, Research and Development, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Richardson+PG%22">Richardson PG</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228703985%22">European journal of haematology</searchLink> [Eur J Haematol] 2024 Nov; Vol. 113 (5), pp. 593-605. <i>Date of Electronic Publication: </i>2024 Jul 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Multicenter Study; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Blackwell%22">Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8703985 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1600-0609 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209024441%22">09024441 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38993150
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ejh.14270
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 593
    Titles:
      – TitleFull: An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kapoor P
      – PersonEntity:
          Name:
            NameFull: Nathwani N
      – PersonEntity:
          Name:
            NameFull: Jelinek T
      – PersonEntity:
          Name:
            NameFull: Pour L
      – PersonEntity:
          Name:
            NameFull: Perrot A
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Huang SY
      – PersonEntity:
          Name:
            NameFull: Spicka I
      – PersonEntity:
          Name:
            NameFull: Chhabra S
      – PersonEntity:
          Name:
            NameFull: Lichtman E
      – PersonEntity:
          Name:
            NameFull: Mateos MV
      – PersonEntity:
          Name:
            NameFull: Kanagavel D
      – PersonEntity:
          Name:
            NameFull: Zhao L
      – PersonEntity:
          Name:
            NameFull: Guillemin-Paveau H
      – PersonEntity:
          Name:
            NameFull: Macé S
      – PersonEntity:
          Name:
            NameFull: van de Velde H
      – PersonEntity:
          Name:
            NameFull: Richardson PG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2024 Nov
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1600-0609
          Numbering:
            – Type: volume
              Value: 113
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: European journal of haematology
              Type: main
ResultId 1